Moreover, the trial, Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis (NCT05191342), will assess the expression and significance of PCSK9 in RA patients, while the study, titled “Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers” (NCT04781322), is projected to conclude its primary phase in December 2023 to measure the impact of PCSK9-iT on heavy drinkers. This evidence concerns the gene PCSK9 and rheumatoid arthritis.